<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04970446</url>
  </required_header>
  <id_info>
    <org_study_id>StvincentsmelbourneMIROII</org_study_id>
    <nct_id>NCT04970446</nct_id>
  </id_info>
  <brief_title>The MIRO II Study: Microbial Restoration in Inflammatory Bowel Diseases</brief_title>
  <acronym>MIRO II</acronym>
  <official_title>The MIRO II Study: Microbial Restoration in Inflammatory Bowel Diseases</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>St Vincent's Hospital Melbourne</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>The Queen Elizabeth Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>BiomeBank Adelaide</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>The University of Queensland</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Monash University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>St Vincent's Hospital Melbourne</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a prospective, two-centre, double-blind, parallel-arm, randomised, placebo-controlled&#xD;
      trial evaluating the impact of FMT on patients with active Crohn's disease.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The study will be conducted in two parts. The first part will involve all patients undergoing&#xD;
      an optimisation phase, followed by randomisation into either intervention or placebo arms of&#xD;
      the induction phase of the study. For patients achieving a pre-determined clinical response&#xD;
      threshold at week 8 they will be re-randomised into the maintenance phase of the trial for a&#xD;
      further 44 weeks.&#xD;
&#xD;
      FMT will be anaerobically prepared, freeze-thawed for administration.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">August 1, 2021</start_date>
  <completion_date type="Anticipated">December 1, 2023</completion_date>
  <primary_completion_date type="Anticipated">December 1, 2022</primary_completion_date>
  <phase>Phase 2/Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>Prospective, two clinical center, parallel-arm, randomised, double-blind, placebo-controlled trial</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
    <masking_description>Randomisation tables will be computer generated by an independent statistician. The indistinguishable aspect of the FMT syringes (colour, packaging) will ensure the blindness of both patients and physicians in charge.</masking_description>
  </study_design_info>
  <primary_outcome>
    <measure>Clinical response</measure>
    <time_frame>Week 8</time_frame>
    <description>CDAI decrease of ≥100 or CDAI&lt;150</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">120</enrollment>
  <condition>Fecal Microbiota Transplantation</condition>
  <condition>Crohn Disease</condition>
  <condition>Inflammatory Bowel Diseases</condition>
  <condition>Microbiome</condition>
  <arm_group>
    <arm_group_label>FMT arm</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Anaerobically prepared, freeze-thawed faecal microbiota transplantation</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo arm</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo liquid formulation (normal saline, glycerol, food colorant)</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Antibiotics</intervention_name>
    <description>All patients will receive a one week course of antibiotic therapy.</description>
    <arm_group_label>FMT arm</arm_group_label>
    <arm_group_label>Placebo arm</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>Dietician designed diet</intervention_name>
    <description>All patients will be recommended dietary modification 3 weeks prior to, and during, the study.</description>
    <arm_group_label>FMT arm</arm_group_label>
    <arm_group_label>Placebo arm</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>FMT</intervention_name>
    <description>Anaerobically prepared stool. Dosing will vary according to mode of administration.</description>
    <arm_group_label>FMT arm</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Placebo will contain food colourant, 0.9% normal saline and glycerol.</description>
    <arm_group_label>Placebo arm</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
        • Active Crohn's disease&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Active perianal or fistulising disease&#xD;
&#xD;
          -  Pregnant&#xD;
&#xD;
          -  Enteropathy or colitis other than Crohn's disease&#xD;
&#xD;
          -  Symptomatic stricture likely to require surgical treatment&#xD;
&#xD;
          -  Presence of a stoma&#xD;
&#xD;
          -  Presence of an ileoanal pouch&#xD;
&#xD;
          -  Immunodeficiency (beyond that caused by immune suppressants used with IBD) e.g. HIV or&#xD;
             Common variable immune deficiency&#xD;
&#xD;
          -  Prednisolone dose &gt;20mg or budesonide dose &gt;6mg&#xD;
&#xD;
          -  Active gastrointestinal infection&#xD;
&#xD;
          -  Alcohol consumption of a dependent nature&#xD;
&#xD;
          -  Primary sclerosing cholangitis&#xD;
&#xD;
          -  Recent overseas travel&#xD;
&#xD;
          -  Contact with COVID-19 positive or DHHS-defined close contact of COVID-19 positive&#xD;
             individual in 8 weeks prior to study entry&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Michael A Kamm, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>St Vincents Hospital</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Amy Wilson O'Brien</last_name>
    <phone>+61430461146</phone>
    <email>amy.wilson-obrien@svha.org.au</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Sasha Fehily, MD</last_name>
  </overall_contact_backup>
  <verification_date>July 2021</verification_date>
  <study_first_submitted>July 18, 2021</study_first_submitted>
  <study_first_submitted_qc>July 18, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">July 21, 2021</study_first_posted>
  <last_update_submitted>July 18, 2021</last_update_submitted>
  <last_update_submitted_qc>July 18, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">July 21, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>St Vincent's Hospital Melbourne</investigator_affiliation>
    <investigator_full_name>Michael Kamm</investigator_full_name>
    <investigator_title>The MIRO II Study: Microbial Restoration in Inflammatory Bowel Diseases</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Crohn Disease</mesh_term>
    <mesh_term>Intestinal Diseases</mesh_term>
    <mesh_term>Inflammatory Bowel Diseases</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Anti-Bacterial Agents</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_info_type>Statistical Analysis Plan (SAP)</ipd_info_type>
    <ipd_time_frame>When data becomes available</ipd_time_frame>
    <ipd_access_criteria>TBC</ipd_access_criteria>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

